Hester Biosciences Limited (HESTERBIO.BO)
INR 2469.0
(1.32%)
INR 2469.0
(1.32%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 364.81 Million INR | 17.58% |
| 2022 | 310.27 Million INR | -28.91% |
| 2021 | 436.43 Million INR | -23.14% |
| 2020 | 567.84 Million INR | 32.85% |
| 2019 | 427.43 Million INR | -24.61% |
| 2018 | 566.93 Million INR | 49.26% |
| 2017 | 379.81 Million INR | 23.38% |
| 2016 | 307.85 Million INR | 24.09% |
| 2015 | 248.07 Million INR | 36.33% |
| 2014 | 181.97 Million INR | 36.34% |
| 2013 | 133.46 Million INR | -7.35% |
| 2012 | 144.06 Million INR | 21.09% |
| 2011 | 118.96 Million INR | 320.83% |
| 2010 | -53.87 Million INR | -145.04% |
| 2009 | 119.62 Million INR | 8.36% |
| 2008 | 110.39 Million INR | -18.61% |
| 2007 | 135.64 Million INR | 57.11% |
| 2006 | 86.33 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | 149.59 Million INR | 10.68% |
| 2024 Q1 | 135.16 Million INR | 10.97% |
| 2023 Q4 | 121.8 Million INR | 90.13% |
| 2023 FY | 364.81 Million INR | 17.58% |
| 2023 Q1 | 89.64 Million INR | 42.06% |
| 2023 Q3 | 64.06 Million INR | -28.27% |
| 2023 Q2 | 89.31 Million INR | -0.37% |
| 2022 Q3 | 135.19 Million INR | 75.23% |
| 2022 Q4 | 63.1 Million INR | -53.32% |
| 2022 FY | 310.27 Million INR | -28.91% |
| 2022 Q1 | 23.7 Million INR | -54.37% |
| 2022 Q2 | 77.15 Million INR | 225.53% |
| 2021 Q4 | 51.94 Million INR | -47.33% |
| 2021 FY | 436.43 Million INR | -23.14% |
| 2021 Q2 | 145.07 Million INR | 4.82% |
| 2021 Q3 | 98.61 Million INR | -32.03% |
| 2021 Q1 | 138.4 Million INR | -14.29% |
| 2020 Q4 | 161.47 Million INR | -15.82% |
| 2020 FY | 567.84 Million INR | 32.85% |
| 2020 Q3 | 191.82 Million INR | 49.81% |
| 2020 Q2 | 128.04 Million INR | 35.94% |
| 2020 Q1 | 94.19 Million INR | 20.73% |
| 2019 Q3 | 175.81 Million INR | 106.25% |
| 2019 Q4 | 78.01 Million INR | -55.63% |
| 2019 FY | 427.43 Million INR | -24.61% |
| 2019 Q1 | 149.21 Million INR | -19.29% |
| 2019 Q2 | 85.24 Million INR | -42.87% |
| 2018 Q3 | 177.53 Million INR | 40.85% |
| 2018 Q2 | 126.04 Million INR | -5.35% |
| 2018 Q1 | 133.16 Million INR | 0.0% |
| 2018 FY | 566.93 Million INR | 49.26% |
| 2018 Q4 | 184.87 Million INR | 4.14% |
| 2017 FY | 379.81 Million INR | 23.38% |
| 2016 FY | 307.85 Million INR | 24.09% |
| 2015 FY | 248.07 Million INR | 36.33% |
| 2014 FY | 181.97 Million INR | 36.34% |
| 2013 FY | 133.46 Million INR | -7.35% |
| 2012 Q4 | 24.3 Million INR | -59.37% |
| 2012 FY | 144.06 Million INR | 21.09% |
| 2012 Q1 | 41.45 Million INR | 0.0% |
| 2012 Q2 | 49.22 Million INR | 18.75% |
| 2012 Q3 | 59.81 Million INR | 21.52% |
| 2011 FY | 118.96 Million INR | 320.83% |
| 2010 FY | -53.87 Million INR | -145.04% |
| 2009 FY | 119.62 Million INR | 8.36% |
| 2008 FY | 110.39 Million INR | -18.61% |
| 2007 FY | 135.64 Million INR | 57.11% |
| 2006 FY | 86.33 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Ajanta Pharma Limited | 19.67 Billion INR | 98.146% |
| Amrutanjan Health Care Limited | 457.54 Million INR | 20.268% |
| Sigachi Industries Limited | 1.47 Billion INR | 75.249% |
| Bal Pharma Limited | 233.9 Million INR | -55.962% |
| Ind-Swift Laboratories Limited | 4.42 Billion INR | 91.747% |
| Medico Remedies Limited | 100.3 Million INR | -263.719% |
| Lasa Supergenerics Limited | -458 Million INR | 179.652% |
| Venus Remedies Limited | 534.65 Million INR | 31.767% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 108.865% |
| Alpa Laboratories Limited | 184.49 Million INR | -97.732% |
| Nectar Lifesciences Limited | 923.8 Million INR | 60.51% |
| Shilpa Medicare Limited | 1.36 Billion INR | 73.299% |
| Aarti Drugs Limited | 7.14 Billion INR | 94.897% |
| Lupin Limited | 28.04 Billion INR | 98.699% |
| Aurobindo Pharma Limited | 42.2 Billion INR | 99.136% |
| Zydus Lifesciences Limited | 43.1 Billion INR | 99.154% |
| Windlas Biotech Limited | 1.29 Billion INR | 71.914% |
| Suven Life Sciences Limited | -1.22 Billion INR | 129.76% |
| Eris Lifesciences Limited | 5.18 Billion INR | 92.96% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | 97.446% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 109.468% |
| Ipca Laboratories Limited | 7.98 Billion INR | 95.429% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | 70.365% |
| Achyut Healthcare Limited | 4.43 Million INR | -8120.144% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 99.65% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| RPG Life Sciences Limited | 2.29 Billion INR | 84.085% |
| Mankind Pharma Limited | 21.51 Billion INR | 98.305% |
| Laurus Labs Limited | 3.94 Billion INR | 90.761% |
| Piramal Pharma Limited | 4.55 Billion INR | 91.994% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -46.363% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 98.56% |
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 93.664% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 94.39% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Novartis India Limited | 626.5 Million INR | 41.77% |
| Wanbury Limited | 569.71 Million INR | 35.966% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 92.083% |
| Wockhardt Limited | -670 Million INR | 154.449% |
| Themis Medicare Limited | 392.58 Million INR | 7.076% |
| Jagsonpal Pharmaceuticals Limited | 508.13 Million INR | 28.205% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 92.97% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 95.937% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 99.461% |
| Divi's Laboratories Limited | 33.08 Billion INR | 98.897% |
| NATCO Pharma Limited | 25.96 Billion INR | 98.595% |
| Gufic Biosciences Limited | 1.32 Billion INR | 72.569% |
| IOL Chemicals and Pharmaceuticals Limited | 1.59 Billion INR | 77.154% |
| Ind-Swift Limited | 1.22 Billion INR | 70.243% |
| Procter & Gamble Health Limited | 2.78 Billion INR | 86.906% |
| FDC Limited | 2.98 Billion INR | 87.784% |
| Krebs Biochemicals & Industries Limited | -151.95 Million INR | 340.074% |
| Granules India Limited | 6.81 Billion INR | 94.648% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Alkem Laboratories Limited | 19.46 Billion INR | 98.126% |
| AstraZeneca Pharma India Limited | 1.71 Billion INR | 78.759% |
| Biofil Chemicals and Pharmaceuticals Limited | 9.06 Million INR | -3922.738% |
| Brooks Laboratories Limited | 14.44 Million INR | -2426.385% |
| Megasoft Limited | -121.1 Million INR | 401.237% |
| ZIM Laboratories Limited | 253.82 Million INR | -43.723% |
| Strides Pharma Science Limited | 5.22 Billion INR | 93.019% |
| Neuland Laboratories Limited | 5.31 Billion INR | 93.14% |
| Morepen Laboratories Limited | 4.17 Billion INR | 91.26% |
| Hikal Limited | 32.11 Million INR | -1036.126% |
| Indoco Remedies Limited | 1.29 Billion INR | 71.776% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | 88.338% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -75.347% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -1228.611% |